ReviewNature biotechnology2007
RNA interference against viruses: strike and counterstrike.
Review in Nature biotechnology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 136 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
136 citing papers in PubMed, 295 citations in OpenAlex.
- Experimental infection of acute bee paralysis virus induces differential responses of selected honey bee immune genes, independent of varroa resistance.Scientific reports · 2026Article
- Target, silence, replace: a review on RNA-based drugs in modern medicine.Frontiers in cell and developmental biology · 2026Review
- Exploring the impact of a chemical disinfectant and an antiviral drug for RNA virus management in the Mediterranean fruit fly mass-rearing.Insect science · 2025Article
- Functions and applications of RNA interference and small regulatory RNAs.Acta biochimica et biophysica Sinica · 2024Review
- Small interfering RNA (siRNA)-based therapeutic applications against viruses: principles, potential, and challenges.Journal of biomedical science · 2023Review
- Geminiviral betasatellites: critical viral ammunition to conquer plant immunity.Archives of virology · 2023Review
- Maxizyme-mediated suppression of chikungunya virus replication and transmission in transgenicFrontiers in microbiology · 2023Article
- Bacterial origins of human cell-autonomous innate immune mechanisms.Nature reviews. Immunology · 2022Review
- Constructing the boundary between potent and ineffective siRNAs by MG-algorithm with C-features.BMC bioinformatics · 2022Article
- Nanoparticle Delivery Platforms for RNAi Therapeutics Targeting COVID-19 Disease in the Respiratory Tract.International journal of molecular sciences · 2022Review
- Review
- Constrained peptides mimic a viral suppressor of RNA silencing.Nucleic acids research · 2021Article
- Lipid Nanocarriers for Anti-HIV Therapeutics: A Focus on Physicochemical Properties and Biotechnological Advances.Pharmaceutics · 2021Review
- shRNA transgenic swine display resistance to infection with the foot-and-mouth disease virus.Scientific reports · 2021Article
- Antiviral RISC mainly targets viral mRNA but not genomic RNA of tospovirus.PLoS pathogens · 2021Article
- RNA Interference-Based Forest Protection Products (FPPs) Against Wood-Boring Coleopterans: Hope or Hype?Frontiers in plant science · 2021Review
- Cellular Targeting of Oligonucleotides by Conjugation with Small Molecules.Molecules (Basel, Switzerland) · 2020Review
- Nanoparticles-assisted delivery of antiviral-siRNA as inhalable treatment for human respiratory viruses: A candidate approach against SARS-COV-2.Nano select : open access · 2020Review
- Multiple dengue virus serotypes resistant transgenicRNA biology · 2020Article
- Double-Stranded RNA Technology to Control Insect Pests: Current Status and Challenges.Frontiers in plant science · 2020Review
76 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
RNA interference (RNAi) is a conserved sequence-specific, gene-silencing mechanism that is induced by double-stranded RNA. RNAi holds great promise as a novel nucleic acid-based therapeutic against a wide variety of diseases, including cancer, infectious diseases and genetic disorders. Antiviral RNAi strategies have received much attention and several compounds are currently being tested in clinical trials. Although induced RNAi is able to trigger profound and specific inhibition of virus replication, it is becoming clear that RNAi therapeutics are not as straightforward as we had initially hoped. Difficulties concerning toxicity and delivery to the right cells that earlier hampered the development of antisense-based therapeutics may also apply to RNAi. In addition, there are indications that viruses have evolved ways to escape from RNAi. Proper consideration of all of these issues will be necessary in the design of RNAi-based therapeutics for successful clinical intervention of human pathogenic viruses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.